Fluidigm Maxpar Antibodies
Fluidigm has released more than 100 pathologist-verified Maxpar antibodies for use with imaging mass cytometry on the Hyperion Imaging System. The company's portfolio now includes antibodies verified for use with both formalin-fixed, paraffin-embedded and frozen tissues. Imaging mass cytometry provides visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology, and immune-mediated diseases. Using the dual capability of the Hyperion Imaging System, researchers can deeply profile a wide range of samples from blood to tissues using both mass cytometry and imaging mass cytometry, Fluidigm said.